Please assess the completion status of the following clinical trial:

Trial Title: Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IONIS APO(a)-LRx in Healthy Volunteers With Elevated Lipoprotein(a)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Must have given written informed consent and be able to comply with all study requirements~* Healthy males or females aged 18-65 inclusive and weighing ≥ 50 kg at the time of informed consent~* Females must be non-pregnant and non-lactating, and either surgically sterile or post- menopausal~* Males must be surgically sterile, abstinent or using an acceptable contraceptive method~* BMI \< 35.0 kg/m2~* Subjects must have Lp(a) ≥ 75 nanomoles/liter nmol/L (30 mg/dL) at Screening~Exclusion Criteria:~* Known history of or positive test for human immunodeficiency virus (HIV), hepatitis C or chronic hepatitis B~* Treatment with another Study Drug, biological agent, or device within one-month of screening~* Regular use of alcohol within 6 months of Screening~* Use of concomitant drugs unless authorized by the Sponsor Medical Monitor~* Smoking \> 10 cigarettes a day~* Considered unsuitable for inclusion by the Principal Investigator

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- IONIS-APO(a)-LRx (Type: EXPERIMENTAL): Drug: IONIS-APO(a)-LRx
- Placebo (Normal Saline) (Type: PLACEBO_COMPARATOR): Drug: Sterile Normal Saline (0.9% NaCl)

Based on this trial design, predict the completion outcome and termination type (if applicable).